Tesamorelin vs sermorelin: what the evidence actually shows

Last updated 2026-07-24

What are tesamorelin and sermorelin, and how are they different?

Both drugs are growth hormone releasing hormone (GHRH) analogues. They don't put growth hormone into your body directly. Instead they bind the GHRH receptor on the pituitary and tell it to release more of your own GH, which then drives IGF-1 production in the liver. That's the shared mechanism, and it's where the similarity mostly ends. Tesamorelin is a modified 44-amino acid peptide (a stabilized analogue of human GHRH) that was developed specifically, studied in large randomized trials, and approved by the FDA in 2010 under the brand name Egrifta for reduction of excess visceral adipose tissue in HIV patients with lipodystrophy ^[1][2]. Sermorelin is a shorter fragment, the first 29 amino acids of GHRH, which was the original GH-stimulation test agent studied decades ago. A branded sermorelin product (Geref) existed in the US market at one point but the approved product has been discontinued, and what circulates today as "sermorelin" is compounded or research-grade material, not an FDA-approved drug with a current label. That difference matters more than anything else here. Approved drug with a narrow indication versus discontinued-brand peptide now sold mainly through compounding: that's the single most important fact in this comparison. Everything else (dosing, cost, side effects) sits downstream of it.

Is tesamorelin FDA-approved, and what is it approved for?

Yes. Tesamorelin (Egrifta, and later Egrifta SV) is FDA-approved specifically for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy. It is not approved for general weight loss, for age-related GH decline, for athletic performance, or for cosmetic body recomposition in people without HIV-associated lipodystrophy. The approval rests on two multicenter, double-blind, placebo-controlled phase 3 trials pooled and analyzed together, which found consistent reductions in visceral adipose tissue (VAT) with an acceptable safety profile over 26 weeks, with additional safety data from a longer extension phase ^[3]. A separate post hoc analysis of that same phase 3 program looked specifically at patients with and without dorsocervical fat pads ("buffalo hump") and found tesamorelin's VAT-reduction effect held regardless of that trait ^[4]. Sermorelin has never gone through anything comparable. There is no phase 3 registration trial establishing a body-composition or fat-loss indication for sermorelin under current FDA review. Its evidence base is decades older, smaller, and mostly about diagnosing GH deficiency or short-term GH stimulation testing, not about treating visceral fat.

What does the trial evidence for tesamorelin actually show?

The strongest data point is the pooled phase 3 analysis: two multicenter, double-blind, placebo-controlled trials showed tesamorelin reduced visceral adipose tissue in HIV patients with lipodystrophy, with the reduction sustained through a safety extension period ^[3]. This is the core evidence the FDA approval sits on. Beyond the key trials, a cluster of mechanistic and follow-up studies fills in the picture. A randomized trial found tesamorelin reduced liver fat in HIV-associated NAFLD compared to placebo over a defined treatment period ^[5]. Related work tied visceral fat reduction on tesamorelin to improved liver enzyme levels in the same population ^[6], and transcriptomic and proteomic studies have tried to map the biological pathways behind the hepatic fat response ^[7][8]. A 2021 study reported that tesamorelin improved fat quality (reducing density markers associated with metabolic risk) independent of the raw amount of fat lost, suggesting the drug does something to adipose tissue composition beyond simple volume reduction ^[9]. More recent work has kept testing tesamorelin in updated HIV treatment contexts: a 2024 study evaluated its efficacy and safety in people with HIV specifically on integrase inhibitor regimens (now the dominant first-line HIV therapy class), which matters because integrase inhibitors themselves carry weight-gain effects that complicate the fat picture ^[10]. A 2025 study looked at tesamorelin's effect on neurocognitive impairment in people with HIV and abdominal obesity, an exploratory endpoint well outside the approved indication ^[11]. And a 2026 meta-analysis of randomized controlled trials pooled body composition, hepatic fat, and metabolic and safety outcomes across the tesamorelin trial base in HIV-associated lipodystrophy ^[12]. Sermorelin has nothing at this scale in the modern literature. Its use has consistently rested on decades-old GH stimulation test literature and small studies, and it doesn't appear in the current major trial registries for a defined metabolic or body-composition indication the way tesamorelin does.

How do the dosing and administration protocols compare?

Tesamorelin is dosed as a 2 mg subcutaneous injection once daily, reconstituted from lyophilized powder before injection. It has a defined population pharmacokinetic profile from a published analysis covering both HIV-infected patients and healthy subjects, which described half-life and exposure across the studied dose ^[13]. That PK study is part of why the FDA-approved dose is what it is. It's not a folk-dosing convention. It's derived from measured drug levels in trial subjects. Sermorelin protocols circulating today (typically small nightly subcutaneous doses, often in the range of a few hundred micrograms) come mostly from older GH-axis testing literature and compounding pharmacy practice, not from a current population PK study tied to an FDA-reviewed product. If you're comparing "how much should I take," tesamorelin has a number with regulatory weight behind it. Sermorelin dosing is closer to convention than to trial-derived pharmacology. For anyone actually starting tesamorelin, the practical details, injection technique, reconstitution steps, and how the 2 mg dose is built up from the vial, matter as much as the trial data. See tesamorelin dosage, the tesamorelin dosage calculator, and tesamorelin reconstitution for the how-to layer that sits underneath this evidence comparison.

Which one has better safety and side effect data?

Tesamorelin's safety profile is documented from the phase 3 program plus its safety extension: injection site reactions, joint or muscle pain (arthralgia/myalgia), swelling (edema), and effects on glucose tolerance are the recognized categories, tracked over roughly 52 weeks of combined trial and extension follow-up in the pooled phase 3 analysis ^[3]. Because tesamorelin raises IGF-1, glucose monitoring is part of the standard conversation, and a full side-effect breakdown belongs in a dedicated read: see tesamorelin peptide side effects. Sermorelin's modern safety data is thinner. It's generally described as well-tolerated in the older literature (mostly injection site irritation, flushing, headache), but that literature predates the current compounding-pharmacy distribution model and wasn't built to the same trial standard as the tesamorelin phase 3 program. A broader 2026 review of injectable peptide therapy for orthopaedic and sports medicine use flagged that many peptides used off-label in this space, sermorelin included, lack the kind of controlled safety data that regulatory-approved drugs carry ^[14], and a related 2026 orthopaedic peptides review made a similar point about the evidence gap for musculoskeletal and performance uses of GHRH-class peptides generally ^[15]. A 2026 Sports Medicine review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance drew the same distinction between agents with regulatory-grade safety data and those without ^[16].

Is tesamorelin or sermorelin legal to buy, and what's the regulatory status of each?

Tesamorelin as Egrifta/Egrifta SV is an FDA-approved prescription drug, listed in the FDA's Drugs@FDA database ^[17]. Using it for its approved indication (visceral fat in HIV lipodystrophy) is straightforwardly on-label. Using it for anything else, general fat loss, anti-aging, bodybuilding, is off-label prescribing, which is legal for a physician to do but isn't covered by the trial evidence base described above. Sermorelin's regulatory footprint is murkier. It doesn't currently have an FDA-approved product on the market with an active label, so what's sold as sermorelin is typically produced through compounding. Compounded drugs made from bulk substances are governed by 21 U.S.C. 353a and the associated bulk drug substance lists at 21 CFR 216.23 (503A) and 21 CFR 216.24 (503B) ^[18][19][20]. The FDA maintains and updates the list of bulk substances nominated for compounding use ^[21], and whether a given GHRH peptide sits on an approved bulks list, and under what conditions, changes over time and by compounding category (503A pharmacy vs 503B outsourcing facility). This is a genuinely shifting regulatory area, and anyone considering compounded sermorelin should check current FDA bulk substance status rather than assume yesterday's answer still holds.

How do cost and access compare between the two?

Tesamorelin as branded Egrifta/Egrifta SV runs into the thousands of dollars per month at cash price without insurance coverage, though coverage specifically for the approved HIV lipodystrophy indication brings the out-of-pocket cost down substantially for many patients. Full pricing detail, including what drives the range and where compounded tesamorelin fits into the cost picture, is covered in tesamorelin cost. Sermorelin, sold almost exclusively through compounding pharmacies now, tends to be cheaper per month than branded tesamorelin, often framed as an entry-level GH-axis peptide for that reason. But price comparisons across compounded products are unstable: potency, sourcing quality, and reconstitution practices vary by pharmacy in ways that a national insurance-backed brand doesn't have to contend with. Cheaper isn't automatically a better deal if the product's actual GHRH content or purity is inconsistent, and unlike Egrifta, there's no FDA lot-release standard backing a compounded sermorelin vial.

Which peptide has stronger visceral fat and metabolic evidence?

Tesamorelin, without much competition. The approved indication is literally visceral fat reduction in HIV lipodystrophy, built on pooled phase 3 trial data ^[3], reinforced by a 2026 meta-analysis of randomized controlled trials pooling body composition and metabolic outcomes across the tesamorelin evidence base ^[12]. Related trials tie that VAT reduction to downstream metabolic benefits: improved liver enzymes ^[6], reduced liver fat in NAFLD ^[5], and even improved fat quality independent of quantity lost ^[9]. Sermorelin has no equivalent trial establishing a visceral fat or metabolic endpoint. Its historical use case, GH stimulation testing and general GH-axis support, is a different question than "does this reduce visceral fat," and nobody has run the phase 3 program on sermorelin that would answer that question with comparable rigor. If visceral fat reduction with real trial backing is the goal, tesamorelin is the drug with that specific evidence, and it's the only one of the two carrying an FDA-approved label for it. Full background on the trial program and mechanism lives at tesamorelin.

Does tesamorelin or sermorelin have research beyond the approved indication?

Both do, and it's worth being honest that most of it is early or exploratory. For tesamorelin, that includes the 2025 neurocognitive impairment study in HIV patients with abdominal obesity ^[11], inflammatory marker studies tying VAT reduction to reduced inflammation markers in HIV patients with excess abdominal fat ^[22], and hepatic transcriptomic and proteomic work trying to explain the liver fat effect at a molecular level ^[7][8]. None of this expands the approved indication; it's mechanistic and exploratory research, not new label claims. For GHRH analogues broadly, a 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews covered therapeutic peptide applications and challenges in orthopaedics ^[15], and a 2026 International Journal of Molecular Sciences review covered therapeutic peptides across aesthetic, metabolic, and endocrine conditions more broadly ^[23]. These reviews are useful for context on where the peptide field is heading, but they are reviews of the broader class, not new trial data specific to sermorelin's efficacy.

What about drug detection, doping, and anti-aging use?

Because GHRH analogues stimulate the same GH axis that anabolic and performance-enhancing users care about, both tesamorelin and sermorelin fall under anti-doping scrutiny. A 2021 paper in Drug Testing and Analysis specifically covered advances in detecting synthetic GHRH analogues, tesamorelin included, reflecting that these peptides are monitored substances in competitive sport ^[24]. Neither drug is approved for anti-aging or general athletic performance use, regardless of what gets marketed informally. The aging-related GH decline literature (reviewed, for instance, in a 2013 Best Practice & Research Clinical Endocrinology & Metabolism paper on growth hormone in the aging male) ^[25] discusses the broader GH-axis decline with age, but that's a different evidence question than whether tesamorelin or sermorelin has trial data supporting their use for that purpose. They don't, at least not at the phase 3 level tesamorelin has for its actual approved indication.

Tesamorelin vs sermorelin: side-by-side comparison

Which should you actually consider, and how do you decide?

If you have HIV-associated lipodystrophy with excess visceral fat, tesamorelin is the drug with an FDA-approved indication and a phase 3 evidence base built specifically for that problem ^[3][17]. That's not a marketing claim, it's the literal approved use. If you don't have that diagnosis and you're looking at either peptide for general fat loss, body recomposition, or anti-aging, you're in off-label territory with both, but the gap in evidence quality between them is real. Tesamorelin at least has trial data on visceral fat and metabolic markers to extrapolate from cautiously, even outside its approved population. Sermorelin doesn't have a comparable modern trial to extrapolate from at all. What we'd actually do: if you're weighing this decision, work with a physician who can confirm whether you meet the lipodystrophy criteria described in the clinical approach literature (see the endocrine society-adjacent review on diagnosing lipodystrophy syndromes) ^[26][27], and get the prescription filled through a provider-reviewed pathway rather than an unverified online seller. Tesamorelin Co's provider-reviewed process connects patients to fulfillment through a licensed pharmacy partner rather than compounding or selling anything itself. That distinction, verified prescription plus licensed pharmacy fulfillment versus an unverified vial from an unregulated seller, matters more for sermorelin than for tesamorelin, precisely because sermorelin's compounding-based supply chain has fewer FDA-level guardrails than a branded, approved drug does.

Frequently asked questions

Is sermorelin as effective as tesamorelin for fat loss?

There's no direct head-to-head trial answering this. Tesamorelin has FDA-approved, phase 3 trial-backed evidence for visceral fat reduction in HIV lipodystrophy ^[3]. Sermorelin has no comparable modern trial establishing a fat-loss effect, so "as effective" can't be answered with real data. It's an evidence gap, not a proven equivalence.

Can you take tesamorelin and sermorelin together?

There's no published trial data on combining these two GHRH analogues, and doing so isn't part of either drug's studied protocol. Since both act on the same GHRH receptor pathway, stacking them wouldn't have an obvious mechanistic rationale beyond what either does alone, and it introduces safety and monitoring questions with no trial evidence to answer them.

Is tesamorelin FDA-approved and is sermorelin FDA-approved?

Tesamorelin (Egrifta, later Egrifta SV) is FDA-approved for reducing excess visceral fat in HIV patients with lipodystrophy, per Drugs@FDA ^[17][1]. Sermorelin does not currently have an FDA-approved product on the market; what's sold today is generally compounded from bulk substance under 21 U.S.C. 353a ^[18].

Why did the FDA approve tesamorelin but not sermorelin for fat loss?

Tesamorelin went through a full phase 3 program (two multicenter, double-blind, placebo-controlled trials) specifically targeting visceral adipose tissue in HIV lipodystrophy ^[3]. Sermorelin's development history predates that kind of indication-specific trial program and was mostly built around GH stimulation testing, not a fat-reduction claim, so it never had the trial package needed for that approval.

What is the approved dose of tesamorelin and how does it compare to typical sermorelin dosing?

Tesamorelin's approved dose is 2 mg subcutaneously once daily, with population pharmacokinetics published from trial data ^[13]. Sermorelin protocols (often a few hundred micrograms nightly) come from older GH-testing literature and compounding pharmacy convention rather than a current FDA-reviewed dosing study.

Does insurance cover tesamorelin or sermorelin?

Tesamorelin can be covered when prescribed for its approved indication, HIV-associated lipodystrophy with excess visceral fat, though coverage varies by plan. Sermorelin, sold through compounding, generally isn't covered by insurance since it isn't an FDA-approved product with an indication tied to a covered diagnosis.

What are the main side effects of tesamorelin compared to sermorelin?

Tesamorelin's documented side effects from phase 3 trials include injection site reactions, joint and muscle pain, swelling, and effects on glucose tolerance tracked over roughly a year of trial and extension follow-up ^[3]. Sermorelin's side effect profile in modern literature is thinner and less rigorously studied; reviews of injectable peptide therapy have flagged this evidence gap directly ^[14].

Is sermorelin legal to buy online?

It depends on the source and current regulatory status. Compounded peptides sold from bulk substances fall under 21 U.S.C. 353a and the FDA's bulk drug substance lists at 21 CFR 216.23 and 216.24 ^[18][19][20], and what's permitted shifts over time. Buying from an unverified online seller with no prescription is a different, riskier situation than getting it through a licensed pharmacy with physician oversight.

Can tesamorelin be used for general anti-aging or bodybuilding, more than HIV lipodystrophy?

It can be prescribed off-label for that, but there's no phase 3 trial establishing efficacy or safety for anti-aging or bodybuilding use specifically. The approved evidence base is for visceral fat reduction in HIV-associated lipodystrophy ^[3][1]. Off-label use is a physician decision, not something the trial data directly supports.

Does tesamorelin help with liver fat (NAFLD), and does sermorelin have similar data?

Yes for tesamorelin: a randomized, double-blind, multicenter trial found it reduced liver fat in HIV-associated NAFLD versus placebo ^[5], and a separate study tied visceral fat reduction to improved liver enzymes ^[6]. Sermorelin has no comparable liver fat trial in the current literature.

What's the difference in molecular structure between tesamorelin and sermorelin?

Tesamorelin is a modified 44-amino acid GHRH analogue with a stabilizing modification designed to resist enzymatic breakdown ^[2]. Sermorelin is the first 29 amino acids of native human GHRH, an unmodified fragment. That structural stability difference is part of why tesamorelin was developed further into a full drug program while sermorelin remained closer to its original diagnostic-testing form.

Are tesamorelin and sermorelin banned in competitive sports?

Both fall under anti-doping scrutiny as GHRH-class peptides that stimulate the same growth hormone axis performance-enhancing users target. A 2021 Drug Testing and Analysis paper specifically covered advances in detecting synthetic GHRH analogues including tesamorelin, reflecting active monitoring of this drug class in sport ^[24].

Sources

1. PubMed, Tesamorelin (2019 review): Tesamorelin is FDA-approved for reduction of excess visceral adipose tissue in HIV patients with lipodystrophy
2. PubMed, Tesamorelin, Nature Reviews Drug Discovery (2011): Tesamorelin is a modified, stabilized GHRH analogue developed and approved as Egrifta
3. PubMed, Effects of tesamorelin (TH9507) pooled phase 3 analysis, J Clin Endocrinol Metab (2010): Two pooled multicenter, double-blind, placebo-controlled phase 3 trials showed tesamorelin reduced visceral adipose tissue with safety data through an extension phase
4. PubMed, Effect of tesamorelin with and without dorsocervical fat, J Clin Transl Sci (2023): Post hoc analysis of the phase 3 trial found tesamorelin's VAT-reduction effect held regardless of dorsocervical fat pad presence
5. PubMed, Effects of tesamorelin on NAFLD in HIV, The Lancet HIV (2019): Randomized, double-blind, multicenter trial found tesamorelin reduced liver fat in HIV-associated NAFLD versus placebo
6. PubMed, Visceral fat reduction with tesamorelin and liver enzymes, AIDS (2017): Visceral fat reduction with tesamorelin was associated with improved liver enzyme levels in HIV patients
7. PubMed, Effects of tesamorelin on hepatic transcriptomic signatures, JCI Insight (2020): Study examined hepatic transcriptomic signatures underlying tesamorelin's effect on HIV-associated NAFLD
8. PubMed, Delineating tesamorelin response pathways, Scientific Reports (2021): Targeted proteomic and transcriptomic study mapped tesamorelin response pathways in HIV-associated NAFLD
9. PubMed, Tesamorelin improves fat quality independent of fat quantity, AIDS (2021): Tesamorelin improved fat quality markers independent of the amount of fat lost
10. PubMed, Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors, AIDS (2024): Study evaluated tesamorelin efficacy and safety specifically in people with HIV on integrase inhibitor regimens
11. PubMed, Effects of Tesamorelin on Neurocognitive Impairment in HIV, J Infect Dis (2025): 2025 study examined tesamorelin's effect on neurocognitive impairment in people with HIV and abdominal obesity
12. PubMed, Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin meta-analysis, Obes Res Clin Pract (2026): 2026 meta-analysis of randomized controlled trials pooled body composition, hepatic fat, metabolic and safety outcomes for tesamorelin
13. PubMed, Population pharmacokinetic analysis of tesamorelin, Clin Pharmacokinet (2015): Population PK analysis described tesamorelin exposure and pharmacokinetics in HIV-infected patients and healthy subjects
14. PubMed, Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians, Am J Sports Med (2026): Review flagged that many peptides used off-label, including GHRH-class agents, lack controlled safety data comparable to approved drugs
15. PubMed, Therapeutic Peptides in Orthopaedics, JAAOS Glob Res Rev (2026): 2026 review covered therapeutic peptide applications, challenges, and evidence gaps in orthopaedic use
16. PubMed, Safety and Efficacy of Approved and Unapproved Peptide Therapies, Sports Med (2026): 2026 review distinguished safety and efficacy evidence between FDA-approved and unapproved peptide therapies for musculoskeletal and athletic use
17. FDA, Drugs@FDA database: Tesamorelin (Egrifta/Egrifta SV) is listed as an FDA-approved drug product
18. Cornell Law/Legal Information Institute, 21 U.S.C. 353a: Pharmacy compounding of drugs from bulk substances is governed by federal statute 21 U.S.C. 353a
19. eCFR, 21 CFR 216.23 (503A Bulks List): 21 CFR 216.23 establishes the list of bulk drug substances that can be used in 503A compounding
20. eCFR, 21 CFR 216.24 (503B Bulks List): 21 CFR 216.24 establishes the list of bulk drug substances for use in 503B outsourcing facility compounding
21. FDA, Bulk drug substances nominated for use in compounding (current list): FDA maintains a current list of bulk drug substances nominated for use in compounding
22. PubMed, Effects of tesamorelin on inflammatory markers, AIDS (2011): Study linked tesamorelin's visceral fat reduction to reduced inflammatory markers in HIV patients with excess abdominal fat
23. PubMed, Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions, Int J Mol Sci (2026): 2026 review covered therapeutic peptides broadly across aesthetic, metabolic, and endocrine applications
24. PubMed, Advances in the detection of GHRH synthetic analogs, Drug Test Anal (2021): 2021 paper covered advances in detecting synthetic GHRH analogues, including tesamorelin, for anti-doping purposes
25. PubMed, Growth hormone in the aging male, Best Pract Res Clin Endocrinol Metab (2013): Review discussed age-related decline of the growth hormone axis in men
26. PubMed, Approach to the Patient With Lipodystrophy, J Clin Endocrinol Metab (2022): Clinical review described diagnostic approach to lipodystrophy syndromes
27. PubMed, How to diagnose a lipodystrophy syndrome, Ann Endocrinol (2012): Paper outlined diagnostic criteria and approach for lipodystrophy syndromes